Vanadyl sulfate treatment stimulates proliferation and regeneration of beta cells in pancreatic islets

Journal of Diabetes Research

Volumn 2014, Issue , 2014, Pages

  Missaoui, Samira ^a   Rhouma, Khémais Ben ^a   Yacoubi, Mohamed Tahar ^b   Sakly, Mohsen ^a   Tebourbi, Olfa ^a  

^a Struggle and Prevention   (Tunisia)

^b FARHAT HACHED HOSPITAL   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; VANADYL SULFATE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; STREPTOZOCIN; VANADIUM DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL PROLIFERATION; CELL REGENERATION; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INSULIN SENSITIVITY; INSULINEMIA; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TREATMENT DURATION; ANIMAL; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; METABOLISM; PATHOLOGY; REGENERATION; TIME; WISTAR RAT;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; RATS, WISTAR; REGENERATION; STREPTOZOCIN; TIME FACTORS; VANADIUM COMPOUNDS;

EID: 84907392646     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2014/540242     Document Type: Article

References (43)

1. M. M. Shafer, B. M. Toner, J. T. Overdier et al., "Chemical speciation of vanadium in particulate matter emitted from diesel vehicles and urban atmospheric aerosols," Environmental Science and Technology, vol. 46, no. 1, pp. 189-195, 2012.
2. T. Kiss, E. Kiss, E. Garribba, and H. Sakurai, "Speciation of insulin-mimetic VO(IV)-containing drugs in blood serum," Journal of Inorganic Biochemistry, vol. 80, no. 1-2, pp. 65-73, 2000.
3. R. Yanardag, S. Bolkent, Ö. Karabulut-Bulan, and S. Tunali, " Effects of vanadyl sulfate on kidney in experimental diabetes," Biological Trace Element Research, vol. 95, no. 1, pp. 73-85, 2003.
4. M. Koyuturk, S. Tunali, S. Bolkent, and R. Yanardag, "Effects of vanadyl sulfate on liver of streptozotocin-induced diabetic rats," Biological Trace Element Research, vol. 104, no. 3, pp. 233-247, 2005.
5. Y. Niu, W. Liu, C. Tian et al., "Effects of bis(α-furancarboxylato) oxovanadium(IV) on glucose metabolism in fat-fed/strep-tozotocin-diabetic rats," European Journal of Pharmacology, vol. 572, no. 2-3, pp. 213-219, 2007.
6. D. Wei, M. Li, and W. Ding, "Effect of vanadate on gene expression of the insulin signaling pathway in skeletal muscle of streptozotocin-induced diabetic rats," Journal of Biological Inorganic Chemistry, vol. 12, no. 8, pp. 1265-1273, 2007.
7. M. Li, J. J. Smee, W. Ding, and D. C. Crans, "Anti-diabetic effects of sodium 4-amino-2,6-dipicolinatodioxovanadium(V) dihydrate in streptozotocin-induced diabetic rats," Journal of Inorganic Biochemistry, vol. 103, no. 4, pp. 585-589, 2009.
8. K. H. Thompson, J. Lichter, C. LeBel, M. C. Scaife, J. H. McNeill, and C. Orvig, "Vanadium treatment of type 2 diabetes: a view to the future," Journal of Inorganic Biochemistry, vol. 103, no. 4, pp. 554-558, 2009.
9. V. Badmaev, S. Prakash, and M. Majeed, "Vanadium: a review of its potential role in the fight against diabetes," Journal of Alternative and Complementary Medicine, vol. 5, no. 3, pp. 273- 291, 1999.
10. M. C. Cam, R. W. Brownsey, and J. H. McNeill, "Mechanisms of vanadium action: insulin-mimetic or insulin-enhancing agent?" Canadian Journal of Physiology and Pharmacology, vol. 78, no. 10, pp. 829-847, 2000.
11. H. A. Sakurai, K. Tsuchiya, M. Nukatsuka, M. Sofue, and J. Kawada, "Insulin-like effect of vanadyl ion on streptozotocininduced diabetic rats," Journal of Endocrinology, vol. 126, no. 3, pp. 451-459, 1990.
12. M. T. Conconi, E. Decarlo, S. Vigolo et al., "Effects of some vanadyl coordination compounds on the in vitro insulin release from rat pancreatic islets," Hormone and Metabolic Research, vol. 35, no. 7, pp. 402-406, 2003.
13. Y. Shechter, I. Goldwaser, M. Mironchik, M. Fridkin, and D. Gefel, "Historic perspective and recent developments on the insulin-like actions of vanadium; toward developing vanadium-based drugs for diabetes," Coordination Chemistry Reviews, vol. 237, no. 1-2, pp. 3-11, 2003.
14. N. Venkatesan, A. Avidan, and M. B. Davidson, "Antidiabetic action of vanadyl in rats independent of in vivo insulin-receptor kinase activity," Diabetes, vol. 40, no. 4, pp. 492-498, 1991.
15. E. Tsiani and I. G. Fantus, "Vanadium compounds: biological actions and potential as pharmacological agents," Trends in Endocrinology and Metabolism, vol. 8, no. 2, pp. 51-58, 1997.
16. S. Verma, M. C. Cam, and J. H. McNeill, "Nutritional factors that can favorably influence the glucose/insulin system: vanadium," Journal of the American College of Nutrition, vol. 17, no. 1, pp. 11-18, 1998.
17. D. Rehder, "Biological and medicinal aspects of vanadium," Inorganic Chemistry Communications, vol. 6, no. 5, pp. 604-617, 2003.
18. M. Bendayan and D. Gingras, "Effect of vanadate administration on blood glucose and insulin levels as well as on the exocrine pancreatic function in streptozotocin-diabetic rats," Diabetologia, vol. 32, no. 8, pp. 561-567, 1989.
19. G. A. Dehghani, M. Sotoodeh, and G. R. Omrani, "Trophic effects of vanadium on beta-cells of STZ-induced insulindependent diabetic rats and evidence for long term relief of diabetes mellitus," Indian Journal of Medical Research, vol. 110, pp. 70-75, 1999.
20. A. K. Srivastava, "Anti-diabetic and toxic effects of vanadium compounds," Molecular and Cellular Biochemistry, vol. 206, no. 1-2, pp. 177-182, 2000.
21. J. J. Mongold, G. H. Cros, L. Vian et al., "Toxicological aspects of vanadyl sulphate on diabetic rats: effects on vanadiumlevels and pancreatic B-cell morphology," Pharmacology and Toxicology, vol. 67, no. 3, pp. 192-198, 1990.
22. J. Yao, M. L. Battell, and J. H. McNeill, "Acute and chronic response to vanadium following two methods of streptozotocin- diabetes induction," Canadian Journal of Physiology and Pharmacology, vol. 75, no. 2, pp. 83-90, 1997.
23. K. Akgün-Dar, S. Bolkent, R. Yanardag, and S. Tunali, "Vanadyl sulfate protects against streptozotocin-induced morphological and biochemical changes in rat aorta," Cell Biochemistry and Function, vol. 25, no. 6, pp. 603-609, 2007.
24. S. Bolkent, S. Bolkent, R. Yanardag, and S. Tunali, "Protective effect of vanadyl sulfate on the pancreas of streptozotocin-induced diabetic rats," Diabetes Research and Clinical Practice, vol. 70, no. 2, pp. 103-109, 2005.
25. C. E. Heyliger, A. G. Tahiliani, and J. H. McNeill, "Effect of Vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats," Science, vol. 227, no. 4693, pp. 1474-1477, 1985.
26. G. A. Dehghani, S. Ahmadi, and G. R. Omrani, "Effects of vanadyl sulphate on glucose homeostasis in severe diabetes induced by streptozotocin in rats," Indian Journal of Medical Research, vol. 106, pp. 481-485, 1997.
27. E. Shafrir, S. Spielman, I. Nachliel, M. Khamaisi, H. Bar-On, and E. Ziv, "Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionally induced diabetes in the Psammomys obesus gerbil," Diabetes/Metabolism Research and Reviews, vol. 17, no. 1, pp. 55-66, 2001.
28. M. Huang, Y. Wu, N. Wang, Z. Wang, Yang X., and P. Zhao, "Is the hypoglycemic action of vanadium compounds related to the suppression of feeding?" Biological Trace Element Research, vol. 157, no. 3, pp. 242-248, 2014.
29. M. Xie, D. Chen, F. Zhang, G. R. Willsky, D. C. Crans, and W. Ding, "Effects of vanadium (III, IV, V)-chlorodipicolinate on glycolysis and antioxidant status in the liver of STZ-induced diabetic rats," Journal of Inorganic Biochemistry, vol. 136, pp. 47- 56, 2014.
30. M. Soveid, G. A. Dehghani, and G. R. Omrani, "Long- term efficacy and safety of vanadium in the treatment of type 1 diabetes," Archives of Iranian Medicine, vol. 16, no. 7, pp. 408- 411, 2013.
31. J. Meyerovitch, Z. Farfel, J. Sack, and Y. Shechter, "Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action," Journal of Biological Chemistry, vol. 262, no. 14, pp. 6658-6662, 1987.
32. A. B. Goldfine, D. C. Simonson, F. Folli, M. E. Patti, and C. R. Kahn, "In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus," Molecular and Cellular Biochemistry, vol. 153, pp. 217-231, 1995.
33. M. C. Cam, B. Rodrigues, and J. H. McNeill, "Distinct glucose lowering and beta cell protective effects of vanadium and food restriction in streptozotocin-diabetes," European Journal of Endocrinology, vol. 141, no. 5, pp. 546-554, 1999.
34. G. Vardatsikos, M. Z. Mehdi, and A. K. Srivastava, "Bis(maltolato)-oxovanadium (IV)-induced phosphorylation of PKB, GSK-3 and FOXO1 contributes toits glucoregulatory responses," International Journal of Molecular Medicine, vol. 24, no. 3, pp. 303-309, 2009.
35. D. C. Crans, J. J. Smee, E. Gaidamauskas, and L. Yang, "The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds," Chemical Reviews, vol. 104, no. 2, pp. 849-902, 2004.
36. T. Scior, J. A. Guevara-García, F. J. Melendez, H. H. Abdallah, Q. T. Do, and P. Bernard, "Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B," Drug Design, Development and Therapy, vol. 4, pp. 231-242, 2010.
37. T. Scior, H. Mack, J. A. G. García, and W. Koch, "Antidiabetic bis-maltolato-oxovanadium(IV): conversion of inactive transto bioactive cis-BMOV for possible binding to target PTP-1B," Drug Design, Development and Therapy, vol. 2, pp. 221-231, 2008.
38. A. Mohammad, V. Sharma, and J. H. McNeill, "Vanadium increases GLUT4 in diabetic rat skeletalmuscle," Molecular and Cellular Biochemistry, vol. 233, no. 1-2, pp. 139-143, 2002.
39. S. Semiz and J. H. McNeill, "Oral treatment with vanadium of Zucker fatty rats activates muscle glycogen synthesis and insulin-stimulated protein phosphatase-1 activity," Molecular and Cellular Biochemistry, vol. 236, no. 1-2, pp. 123-131, 2002.
40. A. Ijaz, T. Tejada, P. Catanuto et al., "Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes," Kidney International, vol. 75, no. 4, pp. 381-388, 2009.
41. A. B. Goldfine, M. E. Patti, L. Zuberi et al., "Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies," Metabolism, vol. 49, no. 3, pp. 400-410, 2000.
42. S. Ahmadi, S. M. Karimian, M. Sotoudeh, M. Bahadori, and G. A. Dehghani, "Pancreatic islet beta cell protective effect of oral vanadyl sulphate in streptozotocin -induced diabetic rats, an ultrastructure study," Pakistan Journal of Biological Sciences, vol. 13, no. 23, pp. 1135-1140, 2010.
43. M. Waguri, K. Yamamoto, J. Miyagawa et al., "Demonstration of two different processes of β-cell regeneration in a new diabetic mouse model induced by selective perfusion of alloxan," Diabetes, vol. 46, no. 8, pp. 1281-1290, 1997.